Photo: The LYVA Labs and PelliTec teams at The Spine
OCUWELL Ltd, a pioneering eye-care technology company and University of Liverpool spin-out, has secured new investment from LYVA Labs, alongside the University of Liverpool, Deepbridge Capital, and Northern Gritstone. The funding will support the commercialisation of OCUWELL’s corneal topography system, designed to improve access to high-quality eye diagnostics worldwide.
Innovating in corneal imaging and ophthalmic diagnostics
Founded in 2022, OCUWELL is developing a next-generation corneal imaging solution comprising two key components: OCUTOP®, a compact handheld device that captures high-resolution corneal data, and OCUGRAPH®, an advanced software suite for detailed analysis and visualisation. Together, these tools provide clinicians and opticians with clinical-grade corneal assessment in a streamlined and accessible format.
This breakthrough builds on over 25 years of research by Professor Ahmed Elsheikh and represents a major advance in ophthalmic diagnostics. With increasing global concern around cornea-related blindness, OCUWELL’s technology provides an essential tool for early detection and better patient care.
Rania Maklad, CEO and co-founder of OCUWELL, said:
“We are delighted to have secured this investment to support us on our journey to democratise access to quality eye care. OCUTOP® was developed in response to a direct request from the market, and the team has worked tirelessly to deliver the initial vision. We are looking forward to the next phase of our journey and to delivering the planned pipeline of products in due course.”
Backing health-tech innovation from Liverpool
The investment will enable OCUWELL to bring its lead product to market and expand its commercial team, further advancing the company’s position as an emerging leader in digital eye health and ophthalmic technology.
Akshay Bhatnagar, Head of Investment at LYVA Labs, said:
“We are delighted to back the team at OCUWELL Ltd to bring their handheld corneal topographer to market. The product will help healthcare providers deal with corneal abnormalities, which, if left untreated, can cause serious deterioration in vision. LYVA Labs are very proud to work alongside Deepbridge Capital and Northern Gritstone in this funding round.”
Supporting healthcare innovation in the Liverpool City Region
This investment reflects the Liverpool City Region’s growing reputation as a hub for health and life sciences innovation. LYVA Labs, supported by the Liverpool City Region Combined Authority, continues to provide equity investment and business support to early-stage companies with the potential for global impact.
Read the full press release here: https://www.ocuwell.com/news/democratise-access-to-eye-care/
